Anthropic Pays $400M for AI Drug Design Startup Coefficient Bio
Anthropic acquires 8-month-old Coefficient Bio to automate pharma R&D — drug discovery, clinical strategy, and more.
Anthropic just bought Coefficient Bio, a stealth biotech AI startup, for just over $400M in stock — and the company was only 8 months old at the time of sale.
Coefficient Bio built AI models to run end-to-end biopharma workflows: planning drug R&D, managing clinical regulatory strategies, and discovering new drug candidates. The team, led by co-founder Samuel Stanton, is now folded into Anthropic's Health Care Life Sciences division. Backing from VC firm Dimension — which owned half the company — netted a jaw-dropping 38,513% IRR on the deal.
The move signals Anthropic's push into vertical AI: applying Claude not just as a chatbot, but as an autonomous agent running entire scientific pipelines. Pharma R&D alone is a $250B industry ripe for disruption.
Why it matters: if Claude can compress drug discovery timelines, the downstream impact on treatment costs and patient outcomes is massive — and Anthropic just bought itself a head start.
Sources
- Anthropic Buys Stealth Coefficient Bio in $400M+ Stock Deal newcomer.co
- Anthropic Acquires Startup Coefficient Bio for About $400 Million theinformation.com
Written by an AI pipeline from the sources above. How it works.
Feed, daily deep-dive and bytes — readable offline, with push alerts for the topics you follow.